Cytokine Signalling Forum

Publications





January 21

Tofacitinib en Artritis Psoriásica: Signos y Síntomas y Calidad de Vida Relacionada con la Salud en dos Estudios Aleatorizados de Fase 3

Merola JF, Papp KA, Nash P, Gratacós J, Boehncke W-H, Thaçi D, Graham D, Hsu M-A, Wang C, Wu J, Young P.
J Eur Acad Dermatol Venereol 2020;34:2809–2820.

Considering the multi-domain nature of PsA, effective treatments must demonstrate efficacy across a range of clinical and patient-reported outcomes. Dermatologic symptoms often precede rheumatic manifestations in people with PsA, typically by 10 years. Tofacitinib demonstrated significant improvements across a range of outcomes including burdensome dermatologic symptoms. This post hoc analysis included data from two double-blind, Phase 3 studies in patients with active PsA and an inadequate res...

Keywords: JAK, Tofacitinib, Clinical, Phase 3